Geron Corporation
33.6M
$1.06B
-10.26
$-0.13
No price alerts set. Add an alert to get notified!
-10.26
3.90
$-0.13
-37.98%
-46.65%
-29.28%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ARVN
Arvinas, Inc.
|
$10.85 | -4.24% | -8.71 | $696.83M | 0.02 |
|
AVBP
ArriVent BioPharma, Inc. Common Stock
|
$24.89 | 2.77% | -5.76 | $1.10B | 0.00 |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$21.45 | 0.14% | -20.66 | $2.22B | 0.01 |
|
LENZ
LENZ Therapeutics, Inc.
|
$9.67 | 3.42% | -3.66 | $303.20M | 0.00 |
|
REPL
Replimune Group, Inc.
|
$8.41 | 10.51% | -2.46 | $694.44M | 0.37 |
|
RZLT
Rezolute, Inc.
|
$3.12 | -0.32% | -3.84 | $298.58M | 0.01 |
|
SVRA
Savara Inc.
|
$5.56 | -0.36% | -10.40 | $1.14B | 0.15 |
|
TYRA
Tyra Biosciences, Inc.
|
$39.61 | 3.47% | -19.68 | $2.13B | 0.02 |
|
VALN
Valneva SE
|
$6.10 | -2.71% | -4.08 | $524.87M | 1.95 |
|
VIR
Vir Biotechnology, Inc.
|
$9.06 | 0.44% | -2.88 | $1.45B | 0.24 |
* Peer stocks are selected based on market capitalization and sector
$2.01
$1.04
$0.00
0.00%
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
